|
Age group
|
Tamoxifen user vs. non-user HR (95 % CI)
|
p-value
|
Interaction p
|
|---|
|
Overall
| | | |
0.29
|
|
<50
|
0.54
|
(0.36-0.82)
|
0.004
| |
|
50-59
|
0.58
|
(0.40-0.83)
|
0.003
| |
|
60-69
|
0.66
|
(0.50-0.88)
|
0.005
| |
|
70+
|
0.59
|
(0.48-0.74)
|
<0.0001
| |
|
Hip fracture
| | | |
0.046
|
|
<50
|
0.39
|
(0.19-0.81)
|
0.01
| |
|
50-59
|
0.38
|
(0.20-0.72)
|
0.003
| |
|
60-69
|
0.56
|
(0.38-0.81)
|
0.002
| |
|
70+
|
0.61
|
(0.47-0.78)
|
0.0001
| |
|
Vertebral fracture
| | | |
0.86
|
|
<50
|
0.59
|
(0.34-1.03)
|
0.06
| |
|
50-59
|
0.74
|
(0.46-1.19)
|
0.21
| |
|
60-69
|
0.84
|
(0.54-1.32)
|
0.46
| |
|
70+
|
0.54
|
(0.34-0.85)
|
0.008
| |
|
Wrist fracture
| | | |
0.26
|
|
<50
|
0.90
|
(0.31-2.57)
|
0.84
| |
|
50-59
|
0.76
|
(0.25-2.34)
|
0.63
| |
|
60-69
|
1.44
|
(0.20-10.6)
|
0.72
| |
|
70+
|
1.10
|
(0.07-17.9)
|
0.94
| |
- Manually adjusted for monthly income, comorbidity and aromatase inhibitor use before the end point
